Merck Seeks To Quash Ranbaxy's Subpoenas

Law360, New York (April 2, 2008, 12:00 AM EDT) -- Merck & Co. Inc. has taken its frustrations over multiple subpoenas from generic-drug maker Ranbaxy Pharmaceuticals Inc. to a judge, claiming that the requests for information on Merck's blood pressure drug Enapren amounted to an international fact-gathering expedition.

In a third-party motion filed Monday, Merck asked the U.S. District Court for the District of New Jersey to quash a recent subpoena for information that Ranbaxy claimed it needed in its ongoing patent litigation with Pfizer Inc. in that court.

Merck said that it had been bombarded...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.